Disease · MONDO_0019086
carcinoma of esophagus
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. carcinoma of esophagus. Diseases, record MONDO_0019086. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019086
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- carcinoma of oesophagus, carcinoma of the esophagus, carcinoma of the oesophagus, esophageal carcinoma, esophagus carcinoma, oesophagus carcinoma
- Open Targets
Drugs39
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 24 | 24 | 24 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 21 | 21 | 20 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 17 | 17 | 17 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 7 | 7 | 6 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| OXALIPLATIN | CHEMBL414804 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 5 | Drugs and targets |
| LEUCOVORIN | CHEMBL1679 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| LEUCOVORIN CALCIUM | CHEMBL1201138 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LOBAPLATIN | CHEMBL4594256 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 39
See all 39 drugsTargets36
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| EGFR | Epidermal growth factor receptor | 3 | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 2 | Programmed cell death 1 ligand 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 2 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 2 | DNA topoisomerase I inhibitor | Phase 2 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TUBA1A | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
| TUBA3C | Tubulin | 2 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7278 | Drugs and targets |
1 to 10 of 36
See all 36 targetsTrials55
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03189719 | First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590) | Phase 3 | 749 | 2021-07-06 | Esophageal Neoplasms | CISPLATIN, FLUOROURACIL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00655876 | Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer | Phase 3 | 344 | 2018-03-14 | Esophageal Cancer | CETUXIMAB, CISPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00590031 | Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan. | Phase 2 | 61 | 2016-01-25 | Esophageal Carcinoma | CISPLATIN, IRINOTECAN | Its record names the disease | ClinicalTrials.gov |
| NCT00193128 | Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer | Phase 1/2 | 59 | 2013-05-13 | Esophagus Cancer | CAPECITABINE, DOCETAXEL, OXALIPLATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03449030 | A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC) | Phase 1 | 31 | 2021-03-22 | Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies | TAK-164 | Its record names the disease | ClinicalTrials.gov |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | Phase 1/2 | 9 | 2023-05-31 | Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas | DECITABINE, PEMBROLIZUMAB, TETRAHYDROURIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT00570531 | Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma | Phase 2 | 6 | 2015-01-12 | Loco-regional Esophageal Cancer | BEVACIZUMAB, CISPLATIN, FLUOROURACIL, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | Phase 1/2 | 3 | 2022-04-05 | Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms, Neoplasms, Germ Cell and Embryonal | PLICAMYCIN | Its record names the disease | ClinicalTrials.gov |
| NCT04949256 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014). | Phase 3 | 863 | Metastatic Esophageal Squamous Cell Carcinoma | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05569668 | Neoadjuvant Chemotherapy Compared With Surgery for Esophageal Carcinoma | 826 | Esophagus Cancer | CISPLATIN, DOCETAXEL, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 55
See all 55 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pembrolizumab + SOC vs Placebo + SOC: deaths from any cause | 331 of 373 | 363 of 376 | 749 | NCT03189719 | Trial comparisons |
| Pembrolizumab + SOC vs Placebo + SOC: Number of Participants With an Adverse Event (AE) | 370 of 370 | 368 of 370 | 740 | NCT03189719 | Trial comparisons |
| Pembrolizumab + SOC vs Placebo + SOC: Number of Participants Discontinuing Study Treatment Due to an AE | 90 of 370 | 74 of 370 | 740 | NCT03189719 | Trial comparisons |
| Pembrolizumab + SOC vs Placebo + SOC: serious adverse events | 207 of 370 | 204 of 370 | 740 | NCT03189719 | Trial comparisons |
| Chemoradiation + Cetuximab vs Chemoradiation: serious adverse events | 88 of 162 | 88 of 173 | 335 | NCT00655876 | Trial comparisons |
| Oxaliplatin/Docetaxel/Radiation (Cohort 1) vs Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2): serious adverse events | 2 of 10 | 33 of 49 | 59 | NCT00193128 | Trial comparisons |
Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 1 of 1 | 2 of 2 | 3 | NCT02859415 | Trial comparisons |
| Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: deaths from any cause | 0 of 1 | 0 of 2 | 3 | NCT02859415 | Trial comparisons |
| Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: Number of Participants With a Dose-limiting Toxicity (DLT) | 0 of 1 | 0 of 2 | 3 | NCT02859415 | Trial comparisons |
| Phase I Dose Level 1 Mithramycin 60 mcg/kg vs Phase I Dose Level -1 Mithramycin 60 mcg/kg Followed by Mithramycin 30 mcg/kg: serious adverse events | 0 of 1 | 2 of 2 | 3 | NCT02859415 | Trial comparisons |
Papers from its trials39
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019086
GET https://conductscience.org/api/diseases/v1/MONDO_0019086/drugs?page=2